Use of Cancer Screening Tests, United States, 2023.

IF 3.9 3区医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Preventing Chronic Disease Pub Date : 2025-08-14 DOI:10.5888/pcd22.250139

Susan A Sabatino, Trevor D Thompson, Jennifer M Croswell, Maria A Villarroel, Juan L Rodriguez, Emily E Adam, Lisa C Richardson

{"title":"Use of Cancer Screening Tests, United States, 2023.","authors":"Susan A Sabatino, Trevor D Thompson, Jennifer M Croswell, Maria A Villarroel, Juan L Rodriguez, Emily E Adam, Lisa C Richardson","doi":"10.5888/pcd22.250139","DOIUrl":null,"url":null,"abstract":"Introduction: The objective of this analysis was to provide national estimates for use of breast, cervical, and colorectal cancer (CRC) screening tests, including for the recently expanded CRC screening age group (ages 45-75 y).Methods: We used data from the 2023 National Health Interview Survey to estimate proportions of screening-eligible adults up to date with breast (women aged 50-74 y), cervical (women aged 21-65 y), and CRC screening (adults aged 45-75 y). We compared breast and CRC estimates age-standardized to the 2000 US standard population to Healthy People 2030 (HP2030) targets. Age-standardized estimates of breast, cervical, and CRC test use were compared with estimates from 2019 (breast, cervical) and 2021 (breast, cervical, CRC).Results: In 2023, estimated percentages of adults up to date were 80.0% (95% CI, 78.7%-81.2%), 75.4% (95% CI, 74.1%-76.6%), and 67.4% (95% CI, 66.3%-68.4%), for breast, cervical, and CRC screening test use, respectively. CRC test use was lower among those aged 45 to 49 years than those aged 50 to 75 years (37.1% vs 73.4%, P < .001). Mammography use approximated the HP2030 target. CRC test use was below the target. Breast, cervical, and CRC screening test use varied with almost all sociodemographic characteristics and health care access, financial hardship, and other barriers examined. Mammography estimates were somewhat higher and cervical test estimates were lower in 2023 than in 2019 and 2021. CRC test use was lower in 2023 than 2021.Conclusion: In 2023, most adults were up to date with breast, cervical, and CRC screening test use; however, 1 in 3 adults (CRC) to 1 in 5 adults (breast) were not. Future monitoring can help determine if changes continue and track progress toward national targets.","PeriodicalId":51273,"journal":{"name":"Preventing Chronic Disease","volume":"22 ","pages":"E52"},"PeriodicalIF":3.9000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360060/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Preventing Chronic Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5888/pcd22.250139","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The objective of this analysis was to provide national estimates for use of breast, cervical, and colorectal cancer (CRC) screening tests, including for the recently expanded CRC screening age group (ages 45-75 y).

Methods: We used data from the 2023 National Health Interview Survey to estimate proportions of screening-eligible adults up to date with breast (women aged 50-74 y), cervical (women aged 21-65 y), and CRC screening (adults aged 45-75 y). We compared breast and CRC estimates age-standardized to the 2000 US standard population to Healthy People 2030 (HP2030) targets. Age-standardized estimates of breast, cervical, and CRC test use were compared with estimates from 2019 (breast, cervical) and 2021 (breast, cervical, CRC).

Results: In 2023, estimated percentages of adults up to date were 80.0% (95% CI, 78.7%-81.2%), 75.4% (95% CI, 74.1%-76.6%), and 67.4% (95% CI, 66.3%-68.4%), for breast, cervical, and CRC screening test use, respectively. CRC test use was lower among those aged 45 to 49 years than those aged 50 to 75 years (37.1% vs 73.4%, P < .001). Mammography use approximated the HP2030 target. CRC test use was below the target. Breast, cervical, and CRC screening test use varied with almost all sociodemographic characteristics and health care access, financial hardship, and other barriers examined. Mammography estimates were somewhat higher and cervical test estimates were lower in 2023 than in 2019 and 2021. CRC test use was lower in 2023 than 2021.

Conclusion: In 2023, most adults were up to date with breast, cervical, and CRC screening test use; however, 1 in 3 adults (CRC) to 1 in 5 adults (breast) were not. Future monitoring can help determine if changes continue and track progress toward national targets.

Abstract Image

查看原文本刊更多论文

癌症筛查测试的使用，美国，2023年。

本分析的目的是为乳腺癌、宫颈癌和结直肠癌（CRC）筛查试验的使用提供全国估计，包括最近扩大的CRC筛查年龄组（45-75岁）。方法：我们使用来自2023年全国健康访谈调查的数据来估计符合筛查条件的成年人中进行乳腺（50-74岁女性）、宫颈（21-65岁女性）和CRC筛查（45-75岁成年人）的比例。我们比较了2000年美国标准人群到健康人群2030 （HP2030）目标的乳腺癌和结直肠癌估计年龄标准化。将乳房、宫颈和结直肠癌检测使用的年龄标准化估计值与2019年（乳房、宫颈）和2021年（乳房、宫颈、结直肠癌）的估计值进行比较。结果：2023年，估计到目前为止，使用乳腺、宫颈和CRC筛查试验的成年人比例分别为80.0% （95% CI, 78.7%-81.2%）、75.4% （95% CI, 74.1%-76.6%）和67.4% （95% CI, 66.3%-68.4%）。45 - 49岁人群CRC检测使用率低于50 - 75岁人群（37.1% vs 73.4%, P < 0.001）。乳房x光检查的使用接近HP2030目标。CRC检测使用率低于目标。乳腺、宫颈和结直肠癌筛查试验的使用几乎随所有社会人口学特征、医疗保健获取、经济困难和其他检查障碍而变化。与2019年和2021年相比，2023年的乳房x光检查估计值略高，宫颈检查估计值略低。2023年CRC检测使用率低于2021年。结论：2023年，大多数成年人使用了最新的乳腺、宫颈和CRC筛查试验；然而，三分之一的成年人（CRC）到五分之一的成年人（乳房）没有。未来的监测可以帮助确定变化是否继续，并跟踪实现国家目标的进展情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Preventing Chronic Disease PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

6.70

自引率

3.60%

发文量

期刊介绍： Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Chronic Disease Prevention and Health Promotion. The mission of PCD is to promote the open exchange of information and knowledge among researchers, practitioners, policy makers, and others who strive to improve the health of the public through chronic disease prevention. The vision of PCD is to be the premier forum where practitioners and policy makers inform research and researchers help practitioners and policy makers more effectively improve the health of the population. Articles focus on preventing and controlling chronic diseases and conditions, promoting health, and examining the biological, behavioral, physical, and social determinants of health and their impact on quality of life, morbidity, and mortality across the life span.